If Streptococcus pneumoniae antigen test is positive and nasal MRSA (methicillin‑resistant Staphylococcus aureus) screen is negative, should vancomycin be discontinued?

Discontinue Vancomycin Based on Negative MRSA Nasal Screen

Yes, you should strongly consider discontinuing vancomycin when the MRSA nasal screen is negative and Streptococcus pneumoniae antigen is positive, as the identified pathogen is S. pneumoniae (not MRSA) and a negative MRSA nasal screen has a 99% negative predictive value for excluding MRSA pneumonia.

Clinical Reasoning

The scenario presents two key pieces of diagnostic information that guide antibiotic de-escalation:

Positive S. pneumoniae Antigen

• This confirms pneumococcal pneumonia as the causative pathogen
• S. pneumoniae does not require vancomycin for treatment
• Appropriate antibiotics include beta-lactams (cefepime, ceftriaxone, piperacillin-tazobactam) or respiratory fluoroquinolones 1

Negative MRSA Nasal Screen

A negative MRSA nasal PCR has exceptional performance characteristics for ruling out MRSA pneumonia:

• Negative predictive value: 99.2-99.6% for MRSA pneumonia 2, 3, 4
• Sensitivity: 88% and specificity: 90.1% 3
• In patients with culture-negative pneumonia where a negative MRSA PCR is obtained, this can reasonably guide antibiotic de-escalation 3

Evidence-Based Approach to Vancomycin Discontinuation

When to Discontinue Vancomycin

Discontinue vancomycin if ALL of the following are met:

• MRSA nasal screen is negative
• Alternative pathogen identified (S. pneumoniae in this case)
• No high-risk features for MRSA (see below)
• Clinical pulmonary infection score (CPIS) ≤6 5

Risk Factors That Would Argue AGAINST Discontinuation

Per IDSA/ATS 2016 guidelines, continue MRSA coverage if 1:

• Prior IV antibiotic use within 90 days
• Hospitalization in a unit where >20% of S. aureus isolates are methicillin-resistant
• High risk of mortality (need for ventilatory support due to pneumonia, septic shock)
• Prior positive MRSA culture or screening

Clinical Impact of De-escalation

Studies demonstrate significant benefits of using negative MRSA nasal screens to guide vancomycin discontinuation:

• Median reduction in vancomycin duration: 16.8 hours (19.9 vs 36.7 hours) 6
• Pharmacist-driven protocols achieve 70% acceptance rate for vancomycin discontinuation within 24 hours 7
• In-hospital mortality with this de-escalation strategy (7.7%) is similar to standard pneumonia management 5
• Estimated cost avoidance: $40 per vancomycin course 7

Recommended Antibiotic Switch

Since S. pneumoniae is confirmed, transition to appropriate pneumococcal coverage:

Preferred agents for proven S. pneumoniae 1:

• Ceftriaxone 1-2g IV daily
• Cefotaxime 1-2g IV q8h
• If penicillin-susceptible: Penicillin G or ampicillin

Alternative agents:

• Respiratory fluoroquinolones (levofloxacin 750mg IV daily)
• Piperacillin-tazobactam 4.5g IV q6h

Important Caveats

Do NOT Discontinue Vancomycin If:

• Patient received IV antibiotics in prior 90 days (risk factor for resistance)
• Patient is critically ill with septic shock or requiring mechanical ventilation
• Local MRSA prevalence >20% in your unit
• Patient has known prior MRSA colonization or infection
• Inadequate clinical response to initial therapy

Timing Considerations

• Discontinue vancomycin within 24-48 hours of negative MRSA nasal screen result 7, 5
• Do not wait for respiratory culture results if nasal screen is negative and alternative pathogen identified
• Ensure appropriate anti-pneumococcal coverage is initiated before stopping vancomycin

Monitoring After Discontinuation

• Reassess clinical response at 48-72 hours
• If clinical deterioration occurs, reconsider MRSA coverage (though this is rare with negative nasal screen)
• The 0.22% rate of subsequent MRSA infection after negative nasal swab supports this approach 2

Avoiding Common Pitfalls

Pitfall #1: Continuing vancomycin "just to be safe" despite negative MRSA screen and identified alternative pathogen

• This increases risk of nephrotoxicity, C. difficile infection, and antimicrobial resistance 1, 8
• Vancomycin-associated acute kidney injury risk increases with prolonged exposure 8

Pitfall #2: Waiting for respiratory culture results before de-escalating

• Negative MRSA nasal screen is sufficient in the context of identified S. pneumoniae 3, 5

Pitfall #3: Ignoring the clinical context

• Always assess for risk factors that would mandate continued MRSA coverage regardless of nasal screen 1